Amarin Board of Directors Announces CEO Transition
04 juin 2024 07h30 HE
|
Amarin Corporation plc
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 ...
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
28 mai 2024 08h15 HE
|
Amarin Corporation plc
-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥...
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
06 mai 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is...
Amarin Reports First Quarter 2024 Business Update and Financial Results
01 mai 2024 07h00 HE
|
Amarin Corporation plc
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus...
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
24 avr. 2024 14h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug...
Amarin Announces Results of Annual General Meeting of Shareholders
22 avr. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024...
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
15 avr. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President &...
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
08 avr. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic...
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
06 avr. 2024 15h30 HE
|
Amarin Corporation plc
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the...
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
03 avr. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent...